How much retatrutide to take per week depends on the trial protocol: studies used 1 mg to 12 mg once weekly with slow titration. Here's what data shows.
There is no approved weekly dose of retatrutide, because retatrutide is not FDA-approved for human use in the United States. In published clinical trials, it was given as a once-weekly subcutaneous injection, and the weekly doses studied ranged from 1 mg to 12 mg, reached through slow step-up titration. Any number you see online for how much retatrutide to take per week comes from those research protocols, not from an approved product label.
That distinction matters. A trial dose is chosen by investigators under medical supervision, with scheduled lab work, dose reductions, and monitoring. Copying a number from a study is not the same as having a prescription or a clinician's oversight.
Why There Is No Standard Weekly Retatrutide Dose
Retatrutide is an investigational triple receptor agonist that activates GLP-1, GIP, and glucagon receptors. It has been tested in phase 2 and phase 3 trials for obesity and type 2 diabetes, but it has not completed the FDA approval process.
Retatrutide remains an investigational drug, so no regulatory agency has approved a weekly dose for weight loss or any other indication.
Three practical consequences follow from that:
- There is no manufacturer label, no package insert, and no official dosing table.
- Products sold online as "retatrutide" are unapproved and unregulated, so purity and actual content are unknown.
- Dose information that circulates in forums is usually a copy of a trial schedule, sometimes with errors.
Weekly Doses Studied in Clinical Trials
The best-known phase 2 trial randomized adults with obesity to placebo or retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, injected once weekly for 48 weeks. Higher dose groups did not start at their target dose; they stepped up gradually to limit gastrointestinal side effects.
| Trial dose group | Reported starting dose | Weekly target dose | Escalation pattern |
|---|---|---|---|
| Low dose | 1 mg | 1 mg | No escalation |
| Mid dose | 2 mg | 4 mg | Step-up about every 4 weeks |
| High dose | 2 mg | 8 mg | Step-up about every 4 weeks |
| Highest dose | 2 mg | 12 mg | Step-up about every 4 weeks |
In that trial, the 12 mg weekly group lost the most weight on average, while also reporting the most nausea, vomiting, and diarrhea. That trade-off between benefit and tolerability is why titration exists in the first place.
Later phase 3 trials in the TRIUMPH program used similar once-weekly dosing with gradual escalation. Results from those studies continue to be reported, so the "best" weekly dose is still an open research question rather than a settled clinical fact.
Where "0.5 Retatrutide" Comes From
Searches for 0.5 retatrutide usually mean one of two things: 0.5 mg of drug, or 0.5 mL drawn into a syringe. No trial dose group used 0.5 mg per week; the lowest studied weekly dose was 1 mg. A 0.5 mL mark, by contrast, is just a volume, and volume only converts to a dose if you know the concentration in the vial.
That conversion is the same math people need for any peptide. If you are trying to understand reconstitution, the logic behind how much bac water to reconstitute 20mg tirzepatide applies here too: milligrams of peptide divided by milliliters of water equals concentration, and concentration determines what a syringe mark actually delivers.
Reconstituted vials also raise sterility, storage, and dosing-error risks that prefilled pens are designed to avoid. Those risks are one reason unapproved peptides are not a do-it-yourself substitute for a prescribed medication.
Injection Frequency and Timing
In trials, retatrutide was injected once per week, on a consistent day, with dose increases spaced roughly four weeks apart. Weekly dosing reflects the drug's half-life; it is not a suggestion that a larger dose can be taken less often.
Schedules differ by compound, and mixing them up is common. Something like how often to take aod 9604 is typically a daily question, while retatrutide in trials was a weekly one. Guessing at frequency is one of the more avoidable mistakes in peptide research.
People also want to know how long does retatrutide take to work. In trial reports, appetite changes often appeared within the first few weeks, while weight differences accumulated over months of titration. The same curiosity drives searches like pt-141 how long does it take to work, but onset data from one drug never transfers to another.
Safety and Legal Considerations
Reported side effects in retatrutide trials include nausea, vomiting, diarrhea, constipation, injection-site reactions, and increases in resting heart rate. Gastrointestinal effects were the most common reason people stopped treatment, and they were dose-related.
Open questions remain about long-term safety, including pancreatic, gallbladder, and thyroid effects seen with related drug classes. Retatrutide is not FDA-approved for human use in the United States, so it cannot be legally prescribed or sold as a finished pharmaceutical product.
Unapproved injectables carry additional hazards: unknown purity, incorrect concentration, contamination, and no guidance if something goes wrong. Injectable "lipo" blends raise the same issues, and people searching how to take lipo c run into an identical problem — unapproved products with no standard dosing and no safety net.
Only a licensed healthcare professional can evaluate whether an approved GLP-1 or dual-agonist medication is appropriate for you, and at what dose.
What to Do Instead of Copying a Trial Dose
If you are considering prescription weight-management medication, the productive path is a clinician visit, not a trial protocol. Approved options exist, they come with labeled dosing, and they can be adjusted based on your side effects and lab results.
If you are reading about retatrutide out of curiosity, treat every specific number as a data point from a study rather than as advice. Dose questions for investigational compounds are answered by investigators and regulators, not by forum consensus.
The bottom line: trial doses of retatrutide were 1 mg to 12 mg once weekly, reached by slow escalation. There is no approved weekly dose available to the public, because retatrutide is not approved at all.
Frequently Asked Questions
How much retatrutide do you take per week?
There is no approved amount. In clinical trials, participants received once-weekly subcutaneous injections of 1 mg, 4 mg, 8 mg, or 12 mg, with higher doses reached through gradual escalation over several weeks. Retatrutide is not FDA-approved for human use, so no official weekly dose exists.
Is 0.5 mg of retatrutide a typical dose?
No. The lowest weekly dose studied in the phase 2 trial was 1 mg, and no trial group used 0.5 mg. When people mention "0.5 retatrutide," they may be referring to 0.5 mL on an insulin syringe, which is a volume rather than a dose.
How long does retatrutide take to start working?
In trial reports, appetite changes often showed up within the first few weeks of treatment. Measurable weight loss accumulated over months as the dose was titrated upward. Timing varies by person, and no one should start or adjust an investigational drug without medical supervision.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.